CIN

Navigating EdTech Uncertainty: Survey Reveals Key Challenges and Opportunities in Administrator Decision-Making

Retrieved on: 
Wednesday, March 13, 2024
LMS, Innovation, Face, University, Education, Educational technology, Knowledge, Policy, Learning, AI, CIN, Faculty, Student, Management

The survey sheds light on critical challenges administrators face in integrating technology into higher education.

Key Points: 
  • The survey sheds light on critical challenges administrators face in integrating technology into higher education.
  • The CIN Administrator EdTech Survey identified four key takeaway areas for institutions and EdTech vendors to improve the EdTech experience for both administrators and students:
    Less than half of administrators are confident in their ability to choose effective EdTech products for their departments or institutions.
  • The overarching goal of the survey is to identify challenges in administrators’ experiences and uncover opportunities to streamline the integration of technology into instruction moving forward.
  • For a full analysis of the survey findings and strategies to improve administrators’ and students’ experience with EdTech, visit www.wgulabs.org/posts/leading-through-change-cin-administrator-edtech-su... .

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Retrieved on: 
Tuesday, March 26, 2024
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Microsoft, Chromosome, Microsoft Research, Survival, Patient, Biomarker, Nature, Cancer, AI, CIN, Human, Medicine, MBA, FRCP, Therapy, CRISPR, Collaboration, Medical imaging

Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.

Key Points: 
  • Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.
  • While CIN is a hallmark of cancer, levels of CIN vary widely across tumor types from being nearly ubiquitous in some to only partially present in others.
  • Volastra’s two KIF18A inhibitors are in parallel Phase 1 clinical trials treating tumor types with near-universally high levels of CIN.
  • We are excited to apply our proprietary precision medicine platform to clinical trials in the rapidly advancing field of KIF18A inhibition.”

Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics

Retrieved on: 
Tuesday, March 26, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Genetics, Partnership, CIN, Medicine, Function, Chromosome, Patient, Neoplasm, Cancer, Disease, CRISPR, Medical imaging

Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).

Key Points: 
  • Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).
  • Function is leveraging its CRISPR-enabled platform to understand disease in unprecedented and patient-specific detail.
  • By moving beyond traditional gene sequencing to measuring gene function, the Volastra and Function teams aim to identify which patients would benefit from treatment with Volastra’s KIF18A inhibitors.
  • CRISPR technology has transformed precision medicine, and we are excited by the potential of Function’s innovative platform to expand the pool of patients that will benefit from KIF18A inhibitors.”

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Hypersensitivity, Pregnancy, Wart, Head, Congress, Recombinant, Multiple endocrine neoplasia, Dizziness, Safety, Vain, Headache, Bruise, Public, Syncope, Ageing, Merck & Co., Cervical intraepithelial neoplasia, Vulvar intraepithelial neoplasia, Anal cancer, Virus-like particle, Observation, CIN, Thigh, Human, HPV, Plant, Vaginal intraepithelial neoplasia, Nausea, MRK, VLP, Investment, Immunity, Fever, Erythema, Vaccination, Injury, Vaccine, Allergy, Itch, AIN, Swelling

Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.

Key Points: 
  • Separately, the company also plans to conduct clinical trials in both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent, recombinant), compared to the approved three-dose regimen.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for expanded HPV type coverage.
  • These randomized, double-blind, multi-year clinical trials will examine the short and long-term efficacy and immunogenicity of a single-dose of GARDASIL 9 versus the currently approved three-dose regimen.

Benchmarks and NC ONEcare Come Together to Revolutionize Healthcare for Children and Families in North Carolina

Retrieved on: 
Monday, April 1, 2024
Organization, Partnership, Hospital, Policy, Child, CIN, Nursing

WILMINGTON, N.C., April 1, 2024 /PRNewswire/ -- Benchmarks, the largest specialty healthcare provider association in North Carolina, and NC ONEcare, LLC, a Clinically Integrated Network (CIN) managed by Alera Health, have announced a groundbreaking partnership aimed at transforming healthcare outcomes for children, adults, and families across the state.

Key Points: 
  • WILMINGTON, N.C., April 1, 2024 /PRNewswire/ -- Benchmarks, the largest specialty healthcare provider association in North Carolina, and NC ONEcare, LLC, a Clinically Integrated Network (CIN) managed by Alera Health, have announced a groundbreaking partnership aimed at transforming healthcare outcomes for children, adults, and families across the state.
  • Through this strategic alliance, Benchmarks and NC ONEcare are poised to lead North Carolina in population health improvement, analytics, training, system of care management, and advocacy, with a singular focus on elevating healthcare access, quality, and equity.
  • Together, they will propel North Carolina towards a vision of a "no wrong door" system of quality care, ensuring that families receive the support and services they need.
  • Peggy Terhune, President/CEO of Monarch, who is also the chair of NC ONEcare, LLC and a member of Benchmarks stated, "I am delighted to see these two organizations partnering.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Vecima Announces Turnkey DAA Packages with RocNet Supply, Speeding 10G Deployments for Smaller Operators

Retrieved on: 
Friday, February 23, 2024
Technology, Audio, Video, Telecommunications, Software, Networks, Internet, Carriers and Services, ONT, TSX, PON, Partnership, Vecima Networks, Product management, DAA, VCM, Workforce, CIN

Vecima Networks Inc. (TSX: VCM) today announced a partnership with RocNet Supply to offer turnkey Distributed Access Architecture (DAA) packages tailored for Remote PHY (R-PHY), Remote MACPHY (R-MACPHY), and PON deployments.

Key Points: 
  • Vecima Networks Inc. (TSX: VCM) today announced a partnership with RocNet Supply to offer turnkey Distributed Access Architecture (DAA) packages tailored for Remote PHY (R-PHY), Remote MACPHY (R-MACPHY), and PON deployments.
  • The turnkey packages, which include Vecima and third-party equipment, are designed to equip operators with all the necessary components to effortlessly transition to 10G networks, streamlining deployment while ensuring compatibility and optimal performance.
  • “We are excited to collaborate with RocNet Supply to introduce these turnkey DAA packages, which mark a significant milestone in simplifying the journey to 10G networks for smaller operators,” stated Scott Raaf, Vice President, Product Management at Vecima Networks.
  • “Our collaboration with Vecima enables us to offer pre-tested turnkey DAA packages, developed with our curated partner ecosystem, that not only simplifies deployment but also accelerates the journey to 10G for smaller operators.”
    In addition to the turnkey DAA packages, Vecima and RocNet provide a suite of professional services to support operators throughout the deployment and configuration process, including network design, training, operations support, workforce optimization, remote lab enablement, and more.

Key Physicians Selects Infina Connect's Intelligent Care Coordinator to Elevate Healthcare Referral Management Across the Triangle Area

Retrieved on: 
Thursday, February 1, 2024
Partnership, Physician, ICC, Patient, Triangle, Communication, CIN, Software as a service, Nursing

CARY, N.C., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Infina Connect, a leading provider of SaaS software for healthcare referral management, is pleased to announce that Key Physicians (Key), the premier Independent Physician Association serving the Triangle of North Carolina, has rekindled its partnership with Infina Connect and selected the Intelligent Care Coordinator (ICC) to optimize its referral management processes.

Key Points: 
  • CARY, N.C., Feb. 1, 2024 /PRNewswire-PRWeb/ -- Infina Connect, a leading provider of SaaS software for healthcare referral management, is pleased to announce that Key Physicians (Key), the premier Independent Physician Association serving the Triangle of North Carolina, has rekindled its partnership with Infina Connect and selected the Intelligent Care Coordinator (ICC) to optimize its referral management processes.
  • Key is getting back to the basics of value-based care..." Jon Fowler, Executive Director, Key Physicians
    Having been a previous heavy user of ICC, Key has a long history of remarkable success with the platform.
  • Due to changing market dynamics, Key found itself in a position to make an independent decision on its referral management platform.
  • "In its initial collaboration with Infina, Key achieved substantial financial savings and operational efficiencies," said Jon Fowler, the executive director of Key Physicians.

CHESS Health Solutions Expands into Medicaid Services, Enhancing Value-based Care in North Carolina

Retrieved on: 
Thursday, January 25, 2024
AMH, MD, CIN, Operation, HITRUST, PHP, Quality, Health, CHESS, Winston-Salem, North Carolina, Value

Winston-Salem, NC, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Winston-Salem, NC - CHESS Health Solutions, a pioneering force in value-based healthcare, is proud to announce its expansion into the Medicaid services market in North Carolina.

Key Points: 
  • Winston-Salem, NC, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Winston-Salem, NC - CHESS Health Solutions, a pioneering force in value-based healthcare, is proud to announce its expansion into the Medicaid services market in North Carolina.
  • “At CHESS, our goal is to be an all-patient solution provider” said Yates Lennon, MD, President of CHESS Health Solutions.
  • CHESS Health Solutions invites healthcare providers, industry experts, and Medicaid Managed Care Organizations to engage with us as we embark on this journey to transform Medicaid services in North Carolina.
  • CHESS Health Solutions is a physician-led company that collaborates with providers and health systems to transform care delivery from a fee-for-service model to value-based care.

Smartlink Data Connector Receives U.S. Patent for Groundbreaking Data Exchange Capabilities in Healthcare

Retrieved on: 
Friday, November 17, 2023
Electronic health record, EHR, HIE, Patient, Improper integral, API, RPA, Integration platform, SDC, Patent, Doctor of Philosophy, Health, CIN, AND, Hi-MD, Registry, Medical imaging, Management

CARY, N.C., Nov. 17, 2023 /PRNewswire-PRWeb/ -- Smartlink Health Solutions, a leader in healthcare integration solutions, proudly announces the issuance of a patent by the United States Patent and Trademark Office (USPTO) for its innovative Smartlink Data Connector (SDC). The patent, numbered US 11,783,922 B1 and titled "SYSTEM, METHOD, AND APPARATUS FOR DATA INTERCHANGE IN CLINICALLY INTEGRATED NETWORKS," solidifies Smartlink's commitment to revolutionizing data exchange in healthcare.

Key Points: 
  • CARY, N.C., Nov. 17, 2023 /PRNewswire-PRWeb/ -- Smartlink Health Solutions, a leader in healthcare integration solutions, proudly announces the issuance of a patent by the United States Patent and Trademark Office (USPTO) for its innovative Smartlink Data Connector (SDC).
  • The patent, numbered US 11,783,922 B1 and titled "SYSTEM, METHOD, AND APPARATUS FOR DATA INTERCHANGE IN CLINICALLY INTEGRATED NETWORKS," solidifies Smartlink's commitment to revolutionizing data exchange in healthcare.
  • This unique feature offers the ability to exchange data with unparalleled flexibility and speed, both extraction and insertion, without predefined APIs.
  • "This patent reinforces Smartlink's unique cutting-edge innovation that goes beyond traditional API or RPA to address the current healthcare data interoperability challenges."